News and Trends 12 Jan 2024
AI and a brain organoid: can this combo take on supercomputers?
Explore the groundbreaking fusion of brain organoids and AI in the creation of Brainoware, the world’s first biohybrid computer.
Research
- Latest Posts
Best in Biotech 11 Jan 2024
Ten NK cell therapy companies to look out for this year
As biotechs raise funding to advance their NK cell therapy candidates in the clinic, here are ten companies in the space to watch out for.
Weekly Roundup 15 Dec 2023
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
Weekly Roundup 8 Dec 2023
Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
News and Trends 1 Dec 2023
Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered
Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]
Weekly Roundup 24 Nov 2023
Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA
Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round Chinese company Viva Biotech closed a funding round worth $210 […]
ADVERTISEMENT
ADVERTISEMENT
Weekly Roundup 10 Nov 2023
Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs
You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]
In Depth 9 Nov 2023
Blood tests for Alzheimer’s: a hit or a miss?
Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]
In Depth 4 Oct 2023
CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?
Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white blood cells that are a […]
News and Trends 18 Sep 2023
Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities
The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […]
In Depth 14 Sep 2023
Righting wrongs: genetic justice for Henrietta Lacks
For what would have been Henrietta Lacks’ 103rd birthday last month, her family, who settled a lawsuit with Thermo Fisher – a multinational biotech company that had used her cells without seeking consent for several years – regarded the win as a “fitting day” for justice. While the settlement took place behind closed doors, where Henrietta […]
Podcast 25 Aug 2023
Beyond Biotech podcast 60 – The cost of research
On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Oncology Drug Attrition […]
ADVERTISEMENT
